Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling nucleosomes. Nu.Q® Discover offers access to a range of assays targeting circulating nucleosomes in plasma as pharmacodynamic biomarkers of epigenetic inhibitors (targeting histone post-translational modifications (PTMs) and to monitor innate immune activation (NETosis) in inflammatory diseases and CAR-T cell therapy). The immunoassays provide non-invasive, quantitative insights, adding significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases.

The assays are available on an automated chemiluminescence bead-based platform as well as manual, ELISA plates and effectively correlate with disease progression and tumor burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes immunoassay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using mass spectrometry, and cell death/toxicity monitoring assays.